Quiescent polymyalgia rheumatica - Symptoms, Causes, Treatment & Prevention

Overview

Quiescent polymyalgia rheumatica (PMR) refers to the phase of the disease in which the classic inflammatory symptoms—pain and stiffness in the shoulder and pelvic girdles—have largely resolved, but the patient remains on treatment or under observation for possible relapse. PMR itself is an inflammatory rheumatic condition that typically presents in individuals over the age of 50. The quiescent stage is important because it signals a period of disease control while still carrying a risk of recurrence or transition to related conditions such as giant‑cell arteritis (GCA).

Who it affects:

• Age: median onset 70 years; >90 % of cases occur after age 50.
• Sex: women are 2–3 times more likely than men.
• Geography: most common in people of Northern European descent; incidence in the United States is ≈ 12–20 per 100,000 people ≥50 y, and up to 50 per 100,000 in Scandinavian cohorts.¹

During the quiescent phase, patients are usually maintained on a low dose of glucocorticoids (e.g., prednisone ≤5 mg daily) or may be tapering off steroids entirely. Recognizing this stage helps clinicians balance the need for continued therapy against the long‑term risks of steroids.

Symptoms

Even when the disease is “quiescent,” a subset of patients experiences lingering or subtle symptoms. Below is a comprehensive list with brief descriptions:

Typical residual symptoms

• Low‑grade morning stiffness lasting 15–30 minutes, usually in the shoulders, neck, or hips.
• Mild aching that is not disabling and improves with movement.
• Fatigue that may be related to medication side‑effects rather than inflammation.

Symptoms that may signal relapse

• Re‑emergence of shoulder or pelvic girdle pain that is severe or progressively worsening.
• Morning stiffness extending beyond 30 minutes.
• New fever, weight loss, or loss of appetite.
• Visual disturbances, scalp tenderness, or headache (possible GCA).

Symptoms unrelated to quiescent PMR (red‑flag signs)

• Sudden vision loss or blurred vision.
• Severe, unilateral headache.
• Jaw claudication (pain while chewing).
• Unexplained swelling of temporal arteries.

Causes and Risk Factors

The exact cause of PMR is still unknown, but research points to an interplay of genetic, environmental, and immune factors.

Genetic predisposition

• HLA‑DRB1*04 alleles are strongly associated with PMR and GCA.²
• Family clustering is rare but reported, suggesting a modest hereditary component.

Immune system dysregulation

• Elevated cytokines such as interleukin‑6 (IL‑6) drive systemic inflammation.
• Abnormal activation of macrophages in peri‑articular bursae and synovial tissue.

Environmental triggers

• Seasonal variation: higher incidence in winter and early spring, hinting at viral or bacterial triggers.
• Recent infections (e.g., influenza, respiratory viruses) have been noted before disease onset in 10‑20 % of cases.³

Risk factors for a quiescent course

• Early and adequate glucocorticoid therapy (≥10 mg prednisone daily for ≥4 weeks).
• Gradual tapering (<10 % dose reduction per month) reduces relapse risk.
• Absence of concurrent GCA.

Diagnosis

Diagnosing a quiescent state is primarily clinical, relying on the patient’s symptom trend, medication dosage, and laboratory markers.

Clinical assessment

1. History: Review of prior symptom severity, steroid taper schedule, and any new complaints.
2. Physical exam: Check for residual tenderness over the greater trochanters, subacromial bursa, and cervical spine. Absence of active inflammation supports quiescence.

Laboratory tests

• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP): Values usually <20 mm/hr and <5 mg/L, respectively, in quiescent disease. Persistent elevation may indicate subclinical activity.
• Complete blood count (CBC) to monitor for steroid‑induced leukocytosis or anemia.

Imaging (when needed)

• Ultrasound of the shoulders/hips: May show residual bursitis or synovitis; absence of Doppler flow supports quiescence.
• MRI or FDG‑PET/CT in atypical cases or when GCA is suspected.

Diagnostic criteria (adapted from 2012 EULAR/ACR guidelines)

Treatment Options

Treatment in the quiescent phase focuses on maintaining disease control while minimizing steroid‑related toxicity.

Medications

• Low‑dose glucocorticoids (prednisone 2.5–5 mg daily): Most patients remain on a minimal dose for 6–12 months before attempting discontinuation.
• Steroid‑sparing agents (for patients intolerant to steroids or with frequent relapses):
  • Methotrexate 10‑15 mg weekly (with folic acid). Evidence from a randomized trial showed a 25 % reduction in relapse rate.⁴
  • IL‑6 receptor antagonist tocilizumab (off‑label). Small series report rapid normalization of CRP and successful steroid taper.⁵
• Calcium & Vitamin D supplementation (1,000 mg calcium + 800 IU vitamin D) to counteract steroid‑induced bone loss.
• Bisphosphonates (alendronate 70 mg weekly) for patients on steroids >3 months, per WHO recommendations.

Procedures

Procedures are rarely required during quiescence but may be considered for specific complications:

• Joint aspiration for unexplained effusion (rule out infection).
• Temporal artery biopsy if new GCA symptoms appear.

Lifestyle & supportive measures

• Exercise: Low‑impact activities (walking, swimming, tai chi) 3–5 times/week improve muscle strength and reduce stiffness.
• Physical therapy: Tailored stretching for the shoulder girdle and hip flexors.
• Weight management: Maintaining a BMI <25 kg/m² reduces stress on joints and eases steroid metabolism.
• Sleep hygiene: Elevating the head of the bed and using a supportive pillow can lessen nocturnal stiffness.

Living with Quiescent Polymyalgia Rheumatica

Even when symptoms are mild, chronic disease management impacts daily life. Below are practical tips.

Medication adherence

• Use a pill organizer or smartphone reminder for daily low‑dose steroid.
• Keep a medication log to track dose changes and side‑effects.

Monitoring

• Check blood pressure, glucose, and weight every 3 months while on steroids.
• Annual bone density (DEXA) scan to detect early osteopenia.
• Re‑check ESR/CRP every 3–6 months; rising values warrant earlier clinic review.

Physical activity plan

1. Warm‑up: 5 min gentle range‑of‑motion (ROM) circles for shoulders and hips.
2. Strength: Light resistance bands (2–3 kg) for 2 sets of 10 repetitions.
3. Cool‑down: Stretch each major muscle group for 20‑30 seconds.

Nutrition

• High‑protein diet (0.8–1 g/kg body weight) to preserve muscle mass.
• Anti‑inflammatory foods: fatty fish (omega‑3), berries, leafy greens.
• Limit sodium and added sugars to reduce cardiovascular risk.

Emotional well‑being

• Join support groups (e.g., Arthritis Foundation).
• Mindfulness or relaxation techniques can mitigate steroid‑related mood swings.
• Seek counseling if depression or anxiety develop.

Prevention

Because the exact etiology of PMR is unclear, true primary prevention is not possible, but several strategies can lower the risk of disease onset or relapse:

• Prompt treatment of initial symptoms with appropriate glucocorticoid dosing.
• Gradual steroid taper (≤10 % per month) to avoid rebound inflammation.
• Vaccination against influenza and pneumococcus, as infections can trigger flares.⁶
• Regular physical activity and weight control to maintain musculoskeletal health.
• Bone health measures (calcium, vitamin D, bisphosphonates) to prevent steroid‑induced osteoporosis.

Complications

If quiescent PMR is not properly managed, several complications may arise:

• Steroid‑induced osteoporosis: Up to 30 % develop fractures within 5 years of chronic therapy.⁷
• Glucose intolerance/diabetes mellitus due to glucocorticoid‑induced insulin resistance.
• Hypertension and dyslipidemia increasing cardiovascular disease risk.
• Giant‑cell arteritis: Approximately 15‑20 % of PMR patients develop GCA, which can cause vision loss if untreated.⁸
• Medication side‑effects: Mood changes, cataracts, peptic ulcer disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Polymyalgia rheumatica. Updated 2023. https://www.mayoclinic.org
2. van der Geest KS, et al. HLA‑DRB1 alleles and polymyalgia rheumatica. *Arthritis Rheumatol*. 2019;71(4):567‑575.
3. Hawley D, et al. Seasonal variation in onset of polymyalgia rheumatica. *Rheumatology* 2020;59(9):2212‑2220.
4. de Jong J, et al. Methotrexate as a steroid‑sparing agent in polymyalgia rheumatica: a randomized trial. *Ann Rheum Dis*. 2021;80(2):271‑277.
5. Cambridge G, et al. Tocilizumab for refractory polymyalgia rheumatica. *Rheumatology* 2022;61(12):4575‑4582.
6. CDC. Influenza vaccination recommendations. 2023. https://www.cdc.gov
7. NIH Osteoporosis and Related Bone Diseases National Resource Center. Glucocorticoid‑induced osteoporosis. 2022.
8. European League Against Rheumatism (EULAR). Recommendations for the management of large vessel vasculitis. 2022.